Nektar Therapeutics
NKTR
155 hedge funds and large institutions have $84.2M invested in Nektar Therapeutics in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 42 increasing their positions, 47 reducing their positions, and 16 closing their positions.
620% more call options, than puts
Call options by funds: $885K | Put options by funds: $123K
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
8% more funds holding
Funds holding: 143 → 155 (+12)
5.52% less ownership
Funds ownership: 72.04% → 66.52% (-5.5%)
11% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 47
32% less capital invested
Capital invested by funds: $124M → $84.2M (-$39.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$3.21M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.45M |
| 3 |
EAM
Exome Asset Management
New York
|
+$1.41M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.04M |
| 5 |
USPCM
Union Square Park Capital Management
New York
|
+$958K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$8.99M |
| 2 |
Millennium Management
New York
|
-$1.95M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.84M |
| 4 |
ACM
Altium Capital Management
New York
|
-$1.7M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.36M |
NKTR Hedge Fund Activity: Q1 2025 in Review
155 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2025, worth a combined $84.2M — down 32% from $124M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NKTR positions and 16 closed out — a net gain of 13 holders — while 42 added to existing stakes and 47 trimmed.
The largest buyer was Almitas Capital, adding an estimated $3.21M. The largest seller was Samlyn Capital, exiting entirely with an estimated $8.99M sold.
- 155 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2025, up from 143 in Q4 2024.
- Funds reported $84.2M of Nektar Therapeutics stock for Q1 2025, down 32% quarter-over-quarter.
- 29 funds opened new Nektar Therapeutics positions in Q1 2025 and 16 closed out, a net change of +13 holders.
- The largest Nektar Therapeutics buyer in Q1 2025 was Almitas Capital, an estimated $3.21M added.
- The largest Nektar Therapeutics seller in Q1 2025 was Samlyn Capital, an estimated $8.99M sold.
Based on aggregated 13F filings for Q1 2025.